ClinicalTrials.gg
CompletedNCT05407311SABREUpdated Nov 17, 2025Results posted

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

A Phase 2 interventional study of 64Cu-SAR-BBN in Biochemical Recurrence of Malignant Neoplasm of Prostate, sponsored by Clarity Pharmaceuticals Ltd. Completed at 8 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Clarity Pharmaceuticals Ltd · Phase 2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with prostate-specific membrane antigen (PSMA)-negative biochemical recurrence of prostate cancer following definitive therapy.

Read the detailed description

Participants with biochemical evidence of recurrence of prostate cancer (PC) were evaluated with 64Cu-SAR-BBN PET/CT (Day 0 and Day 1) and by conventional methodologies up to 180 days later (e.g., histopathology/biopsy, conventional imaging, prostate specific antigen [PSA] reduction post focal salvage therapy or radiotherapy with no concomitant androgen deprivation therapy). Three independent, central readers blinded to the participant number, the time of the PET/CT scan, and the results of the conventional methodologies, assessed the 64Cu-SAR-BBN PET/CT. Three separate independent readers assessed the results of the conventional methodologies.

02

Conditions studied

  • Biochemical Recurrence of Malignant Neoplasm of Prostate
03

In context

Lead sponsor

Clarity Pharmaceuticals Ltd is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. Signed .
  3. ≥ 12 weeks as determined by the Investigator.
  4. confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.
  5. Suspected recurrence of PC based on rising PSA after definitive therapy on the basis of:

    1. Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per American Urological Association recommendation) or
    2. Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per American Society for Therapeutic Radiology and Oncology-Phoenix consensus definition).
  6. Negative or equivocal findings for PC on (1) approved PSMA PET and (2) anatomical imaging (CT and/or magnetic resonance imaging) and (3) if available, any other conventional imaging performed as part of routine standard of care imaging workup within 60 days prior to Day 0.
  7. The Eastern Cooperative Oncology performance status 0-2.
  8. Adequate recovery from acute toxic effects of any prior therapy.
  9. Estimated of 30 mL/min or higher.
  10. Adequate liver function.
  11. For participants who have partners of : Partner and/or participant must use a method of with adequate barrier protection.

Exclusion criteria

Exclusion Criteria:

  1. Participants who received other agents within 28 days prior to Day 0.
  2. Participants administered any high energy (>300 kiloelectronvolts (keV)) gamma-emitting radioisotope within 5 physical half-lives prior to Day 0.
  3. Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy (e.g. androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist) for PC.
  4. Participants who are known to require prohibited treatment (e.g., initiation of androgen-deprivation therapy due to rapidly rising PSA) before the 64Cu-SAR-BBN PET/CT results can be verified via histopathology or follow-up imaging.
  5. Known or expected to 64Cu-SAR-BBN or any of its components.
  6. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    64Cu-SAR-BBN

    Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-BBN.

    Drug: 64Cu-SAR-BBN

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 7 days post injection

  2. Participant-level Correct Detection Rate (CDR) - Day 0

    The percentage of true positive (TP) participants on the Day 0 scan out of all participants with a Day 0 scan.

    Time frame: Day 0 (1-4 hours) post injection

  3. Participant-level CDR - Day 1.

    The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.

    Time frame: Day 1 (24+/-6 Hours) post injection

  4. Region-level Positive Predictive Value (PPV) - Day 0.

    The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.

    Time frame: Day 0 (1-4 hours) post injection

  5. Region-level PPV - Day 1.

    The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.

    Time frame: Day 1 (24 +/- 6 hours) post injection

Secondary outcomes

  1. Biodistribution of 64Cu-SAR-BBN - SUVmean - Day 0

    The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue, bone.

    Time frame: Day 0 (1-4 hours) post injection

  2. Biodistribution of 64Cu-SAR-BBN - SUVmean - Day 1

    The SUVmean in lesions, visceral soft tissue, bone.

    Time frame: Day 1 (24 +/- 6 hours) post injection

  3. Biodistribution of 64Cu-SAR-BBN - SUVmax - Day 0

    The max Standardized Uptake Value (SUVmax) in lesions, visceral soft tissue and bone.

    Time frame: Day 0 (1-4 hours) post injection

  4. Biodistribution of 64Cu-SAR-BBN - SUVmax - Day 1

    The SUVmax in lesions, visceral soft tissue and bone.

    Time frame: Day 1 (24 +/- 6 hours) post injection

  5. Biodistribution of 64Cu-SAR-BBN - SUVr - Day 0

    Standardized Uptake Value Lesion to Background ratio (SUVr): SUVmax of the lesion divided by the SUVmean of gluteus background.

    Time frame: Day 0 (1-4 hours) post injection

  6. Biodistribution of 64Cu-SAR-BBN - SUVr - Day 1

    SUVr: SUVmax of the lesion divided by the SUVmean of gluteus background.

    Time frame: Day 1 (24 +/- 6 hours) post injection

  7. Participant-level PPV

    Percentage of TP participants out of all positive participants, derived separately for each timepoint and reader.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection

  8. Participant-level Detection Rate (DR)

    Percentage of participants with a positive 64Cu-SAR-BBN PET/CT scan out of all participants with a 64Cu-SAR-BBN PET/CT scan for each timepoint and reader.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection

  9. Participant-level False Positive Rate (FPR)

    Percentage of false positive (FP) participants out of all participants with a positive scan, derived separately for each timepoint and reader.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection

  10. Region-level FPR

    Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions, derived separately for each timepoint and reader.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection

  11. Participant-level Discrepant PET Negativity Rate

    Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection

  12. Participant-level True Negative Rate (TNR)

    Percentage of true negative (TN) participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection

  13. Region-level TNR

    Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection

07

Results

Posted Nov 17, 2025

Participant flow

Dates of recruitment period: 19 Sep 2022 to 14 Nov 2023

Participant flow — Overall Study
Milestone64Cu-SAR-BBN
Started53
Completed43
Not completed10
Withdrew: Withdrawal by subject5
Withdrew: Protocol violation3
Withdrew: Physician decision1
Withdrew: Non-compliance1

Outcome measures

PrimarySafety and Tolerability

Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
Up to 7 days post injection
Reported as:
Count of participants · Participants
Safety and Tolerability
Participants64Cu-SAR-BBN
Any TEAE8
TEAE Grade 1 to 28
TEAE Grade 30
TEAE Grade 4 to 50
TEAE Related to 64Cu-SAR-BBN2
Serious TEAE0
TEAE Leading to Discontinuation of Study0
TEAE Leading to Death0
PrimaryParticipant-level Correct Detection Rate (CDR) - Day 0

The percentage of true positive (TP) participants on the Day 0 scan out of all participants with a Day 0 scan.

Time frame:
Day 0 (1-4 hours) post injection
Reported as:
Number · percentage of participants
Participant-level Correct Detection Rate (CDR) - Day 0
percentage of participants64Cu-SAR-BBN
Reader 114.9 (6.2 to 28.3)
Reader 214.9 (6.2 to 28.3)
Reader 314.9 (6.2 to 28.3)
PrimaryParticipant-level CDR - Day 1.

The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.

Time frame:
Day 1 (24+/-6 Hours) post injection
Reported as:
Number · percentage of participants
Participant-level CDR - Day 1.
percentage of participants64Cu-SAR-BBN
Reader 14.3 (0.5 to 14.5)
Reader 210.6 (3.5 to 23.1)
Reader 314.9 (6.2 to 28.3)
PrimaryRegion-level Positive Predictive Value (PPV) - Day 0.

The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.

Time frame:
Day 0 (1-4 hours) post injection
Reported as:
Number · percentage of regions
Region-level Positive Predictive Value (PPV) - Day 0.
percentage of regions64Cu-SAR-BBN
Reader 147.1 (23.0 to 72.2)
Reader 222.6 (9.6 to 41.1)
Reader 333.3 (15.6 to 55.3)
PrimaryRegion-level PPV - Day 1.

The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.

Time frame:
Day 1 (24 +/- 6 hours) post injection
Reported as:
Number · percentage of regions
Region-level PPV - Day 1.
percentage of regions64Cu-SAR-BBN
Reader 122.2 (2.8 to 60.0)
Reader 235.3 (14.2 to 61.7)
Reader 337.5 (18.8 to 59.4)
SecondaryBiodistribution of 64Cu-SAR-BBN - SUVmean - Day 0

The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue, bone.

Time frame:
Day 0 (1-4 hours) post injection
Reported as:
Mean · kg/L
Biodistribution of 64Cu-SAR-BBN - SUVmean - Day 0
kg/LReader 1Reader 2Reader 3
All Lesions5.470 ± 3.20583.773 ± 2.54405.671 ± 8.0303
Soft Tissue Lesions5.699 ± 3.53804.362 ± 2.90506.427 ± 8.5057
Bone Lesions3.703 ± NA2.482 ± 1.29252.353 ± 2.0118
SecondaryBiodistribution of 64Cu-SAR-BBN - SUVmean - Day 1

The SUVmean in lesions, visceral soft tissue, bone.

Time frame:
Day 1 (24 +/- 6 hours) post injection
Reported as:
Mean · kg/L
Biodistribution of 64Cu-SAR-BBN - SUVmean - Day 1
kg/LReader 1Reader 2Reader 3
All Lesions2.586 ± 1.98141.450 ± 1.53051.179 ± 1.5309
Soft Tissue Lesions2.586 ± 1.98141.586 ± 1.77121.652 ± 2.0244
Bone Lesions—2.116 ± 2.36840.772 ± 0.4263
SecondaryBiodistribution of 64Cu-SAR-BBN - SUVmax - Day 0

The max Standardized Uptake Value (SUVmax) in lesions, visceral soft tissue and bone.

Time frame:
Day 0 (1-4 hours) post injection
Reported as:
Mean · kg/L
Biodistribution of 64Cu-SAR-BBN - SUVmax - Day 0
kg/LReader 1Reader 2Reader 3
All Lesions7.335 ± 4.09045.314 ± 3.147114.436 ± 27.7988
Soft Tissue Lesions7.705 ± 4.79525.910 ± 3.855916.368 ± 29.7231
Bone Lesions5.041 ± NA4.144 ± 1.81815.013 ± 3.6903
SecondaryBiodistribution of 64Cu-SAR-BBN - SUVmax - Day 1

The SUVmax in lesions, visceral soft tissue and bone.

Time frame:
Day 1 (24 +/- 6 hours) post injection
Reported as:
Mean · kg/L
Biodistribution of 64Cu-SAR-BBN - SUVmax - Day 1
kg/LReader 1Reader 2Reader 3
All Lesions4.179 ± 3.31732.762 ± 3.54492.763 ± 3.2511
Soft Tissue Lesions4.179 ± 3.31732.930 ± 4.10783.965 ± 4.5243
Bone Lesions—5.017 ± 6.20161.945 ± 0.8572
SecondaryBiodistribution of 64Cu-SAR-BBN - SUVr - Day 0

Standardized Uptake Value Lesion to Background ratio (SUVr): SUVmax of the lesion divided by the SUVmean of gluteus background.

Time frame:
Day 0 (1-4 hours) post injection
Reported as:
Mean · ratio
Biodistribution of 64Cu-SAR-BBN - SUVr - Day 0
ratioReader 1Reader 2Reader 3
Biodistribution of 64Cu-SAR-BBN - SUVr - Day 014.566 ± 8.101610.020 ± 5.188913.442 ± 17.6749
SecondaryBiodistribution of 64Cu-SAR-BBN - SUVr - Day 1

SUVr: SUVmax of the lesion divided by the SUVmean of gluteus background.

Time frame:
Day 1 (24 +/- 6 hours) post injection
Reported as:
Mean · ratio
Biodistribution of 64Cu-SAR-BBN - SUVr - Day 1
ratioReader 1Reader 2Reader 3
Biodistribution of 64Cu-SAR-BBN - SUVr - Day 155.957 ± 36.477140.617 ± 24.741936.254 ± 45.2321
SecondaryParticipant-level PPV

Percentage of TP participants out of all positive participants, derived separately for each timepoint and reader.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Reported as:
Number · percentage of participants
Participant-level PPV
percentage of participantsParticipant-level PPV - Day 0Participant-level PPV - Day 1
Reader 158.3 (27.7 to 84.8)33.3 (4.3 to 77.7)
Reader 231.8 (13.9 to 54.9)38.5 (13.9 to 68.4)
Reader 336.8 (16.3 to 61.6)43.8 (19.8 to 70.1)
SecondaryParticipant-level Detection Rate (DR)

Percentage of participants with a positive 64Cu-SAR-BBN PET/CT scan out of all participants with a 64Cu-SAR-BBN PET/CT scan for each timepoint and reader.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Reported as:
Number · percentage of participants
Participant-level Detection Rate (DR)
percentage of participantsParticipant-level DR - Day 0Participant-level DR - Day 1
Reader 124.5 (13.8 to 38.3)17.0 (8.1 to 29.8)
Reader 243.4 (29.8 to 57.7)28.3 (16.8 to 42.3)
Reader 337.7 (24.8 to 52.1)37.7 (24.8 to 52.1)
SecondaryParticipant-level False Positive Rate (FPR)

Percentage of false positive (FP) participants out of all participants with a positive scan, derived separately for each timepoint and reader.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Reported as:
Number · percentage of participants
Participant-level False Positive Rate (FPR)
percentage of participantsParticipant-level FPR - Day 0Participant-level FPR - Day 1
Reader 141.7 (15.2 to 72.3)66.7 (22.3 to 95.7)
Reader 268.2 (45.1 to 86.1)61.5 (31.6 to 86.1)
Reader 363.2 (38.4 to 83.7)56.3 (29.9 to 80.2)
SecondaryRegion-level FPR

Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions, derived separately for each timepoint and reader.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection
Reported as:
Number · percentage of regions
Region-level FPR
percentage of regionsRegion-level FPR - Day 0Region-level FPR - Day 1
Reader 152.9 (27.8 to 77.0)77.8 (40.0 to 97.2)
Reader 277.4 (58.9 to 90.4)64.7 (38.3 to 85.8)
Reader 366.7 (44.7 to 84.4)62.5 (40.6 to 81.2)
SecondaryParticipant-level Discrepant PET Negativity Rate

Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection
Reported as:
Number · percentage of participants
Participant-level Discrepant PET Negativity Rate
percentage of participants64Cu-SAR-BBN
Reader 126.3 (9.1 to 51.2)
Reader 215.8 (3.4 to 39.6)
Reader 310.5 (1.3 to 33.1)
SecondaryParticipant-level True Negative Rate (TNR)

Percentage of true negative (TN) participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection
Reported as:
Number · percentage of participants
Participant-level True Negative Rate (TNR)
percentage of participantsParticipant-level TNR - Day 0Participant-level TNR - Day 1
Reader 182.1 (63.1 to 93.9)85.7 (67.3 to 96.0)
Reader 257.1 (39.4 to 73.7)77.1 (59.9 to 89.6)
Reader 358.6 (38.9 to 76.5)69.0 (49.2 to 84.7)
SecondaryRegion-level TNR

Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Reported as:
Number · percentage of regions
Region-level TNR
percentage of regionsRegion-level TNR - Day 0Region-level TNR - Day 1
Reader 195.8 (92.2 to 98.1)96.7 (93.4 to 98.7)
Reader 288.2 (82.9 to 92.3)94.6 (90.6 to 97.3)
Reader 392.6 (88.2 to 95.7)93.0 (88.8 to 96.0)

Adverse events

Collected over From time of informed consent up to 7 days post injection. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
64Cu-SAR-BBN0/53 (0%)0/53 (0%)3/53 (5.7%)
Most frequent other events
Most frequent other events
Event64Cu-SAR-BBN
HeadacheNervous system disorders3/53

Baseline characteristics

All enrolled participants who received any amount of 64Cu-SAR-BBN.

Age, Categorical
Age, Categorical(Participants)64Cu-SAR-BBN
<=18 years0
Between 18 and 65 years12
>=65 years41
Sex: Female, Male
Sex: Female, Male(Participants)64Cu-SAR-BBN
Female0
Male53
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)64Cu-SAR-BBN
Hispanic or Latino7
Not Hispanic or Latino46
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)64Cu-SAR-BBN
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White48
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)64Cu-SAR-BBN
United States53
Baseline Prostate Specific Antigen (PSA)
Baseline Prostate Specific Antigen (PSA)(ng/mL)64Cu-SAR-BBN
Mean3.3932 ± 6.13380
08

Study locations

8 sites
  • Tower Urology
    Los Angeles, California 90048, United States
  • Stanford University
    Stanford, California 94305, United States
  • Biogenix Molecular
    Miami, Florida 33165, United States
  • Bamf Health, Inc
    Grand Rapids, Michigan 49503, United States
  • St Louis University Hospital
    St Louis, Missouri 63104, United States
  • GU Research Network
    Omaha, Nebraska 68130, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology San Antonio
    San Antonio, Texas 78258, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in May 2024, 19 months.

Results were first posted in Nov 2025, 1 year 6 months after primary completion. A results delay was requested in Mar 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Jun 7, 2022
StartActual
Sep 19, 2022
Primary completionActual
May 13, 2024
CompletionActual
May 13, 2024
Results delay requested
Mar 26, 2025
Results first posted
Nov 17, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05407311
Lead sponsor
Clarity Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Sep 19, 2022
Primary completion
May 13, 2024
Completion
May 13, 2024
Results posted
Nov 17, 2025
Last update
Nov 17, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sar-bbn CU-64

Start the discussion